{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:10:55Z","timestamp":1793502655428,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The remarkable improvement in survival among individuals with hematological malignancies receiving chimeric antigen receptor (CAR) T-cell therapy has highlighted the growing unmet need to incorporate patient-centered assessments in management guidelines for these patients. That CAR T-cell therapy is associated with unique toxicities and relatively high symptom burden in the first few weeks after cell infusion is well known. Magnifying the patient's voice by using patient-reported outcomes (PROs) might support personalized intervention in the acute-care setting, optimize the use of medical resources, improve satisfaction with therapy, and enhance survival benefit. However, various factors impede PRO use in routine patient care: (1) the feasibility of PRO assessment during the acute phase of treatment, especially in patients experiencing neurological toxicities, is not well established; (2) although PROs are widely used in drug- development trials, the assessment tools used in clinical trials primarily inform quality-of-life or safety comparisons among study arms and are rarely the proper tools for assessing and capturing clinically meaningful adverse events that should be monitored in routine patient care; (3) PRO data that could guide how best to monitor and capture the delayed effects of CAR T-cell therapy in long-term survivors are limited. There is a pressing need to overcome these barriers to integrating evidence-based PROs into standard-of-care guidelines for patients receiving CAR T-cell therapy. In this review, we present the current state of PRO utilization in CAR T-cell therapy. We also discuss practical approaches and future directions for successful implementation of PROs in the care of patients receiving CAR T-cell therapy.<\/jats:p>","DOI":"10.1182\/hematology.2024000536","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:01:54Z","timestamp":1733497314000},"page":"102-108","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies"],"prefix":"10.1182","volume":"2024","author":[{"given":"Xin Shelley","family":"Wang","sequence":"first","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2024121115361942200_hem2024000536C1","unstructured":"Jensen\n              TS\n            , ChinJ, AshbyLM, HakimR, PaserchiaLA, SzaramaKB. Decision memo for chimeric antigen receptor (CAR) T-cell therapy for cancers (CAG-00451N). Accessed 24July, 2024. https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=291."},{"issue":"4","key":"2024121115361942200_hem2024000536C2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024121115361942200_hem2024000536C3","first-page":"1","article-title":"Introduction to cancer symptom science","volume-title":"Cancer Symptom Science: Measurement, Mechanisms, and Management","author":"Cleeland","year":"2011"},{"issue":"5","key":"2024121115361942200_hem2024000536C4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-13-2442","article-title":"Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation","volume":"20","author":"Wang","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024121115361942200_hem2024000536C5","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/cncr.23820","article-title":"Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"2024121115361942200_hem2024000536C6","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s11136-018-1834-3","article-title":"Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study","volume":"27","author":"Yue","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"2024121115361942200_hem2024000536C7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cncr.24703","article-title":"Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer","volume":"116","author":"Wang","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"2024121115361942200_hem2024000536C8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2024121115361942200_hem2024000536C9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2024121115361942200_hem2024000536C10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"2024121115361942200_hem2024000536C11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"2024121115361942200_hem2024000536C12","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2024121115361942200_hem2024000536C13","volume-title":"Core Patient-Reported Outcomes in Cancer Clinical Trials. Guidance for Industry (Draft)","author":"US Food and Drug Administration","year":"2021"},{"key":"2024121115361942200_hem2024000536C14","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"2 5(5)","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024121115361942200_hem2024000536C15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.14100","article-title":"Long-term survivorship care after CAR-T cell therapy","volume":"112","author":"Puckrin","year":"2024","journal-title":"Eur J Haematol"},{"issue":"3","key":"2024121115361942200_hem2024000536C16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2024121115361942200_hem2024000536C17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00108-021-01046-5","article-title":"[Toxicity after chimeric antigen receptor T-cell therapy: Overview and management of early and late onset side effects]","volume":"62","author":"Garcia Borrega","year":"2021","journal-title":"Internist (Berl)"},{"issue":"1","key":"2024121115361942200_hem2024000536C18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 5)(suppl 1)(suppl 5 1","key":"2024121115361942200_hem2024000536C19","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0000000000001037","article-title":"Symptom care at home: a comprehensive and pragmatic PRO system approach to improve cancer symptom care","volume":"57","author":"Mooney","year":"2019","journal-title":"Med Care"},{"issue":"2","key":"2024121115361942200_hem2024000536C20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMp1611252","article-title":"Patient-reported outcomes\u2014harnessing patients' voices to improve clinical care","volume":"376","author":"Basch","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2024121115361942200_hem2024000536C21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient- reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024121115361942200_hem2024000536C22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"2024121115361942200_hem2024000536C23","unstructured":"Eprovide. EORTC quality of life questionnaire\u2014core questionnaire (EORTC QLQ-C30). Accessed 25July2024. https:\/\/eprovide.mapi-trust.org\/instruments\/eortc-quality-of-life-questionnaire-core-questionnaire."},{"issue":"4","key":"2024121115361942200_hem2024000536C24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.31089","article-title":"PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors","volume":"124","author":"Shaw","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"2024121115361942200_hem2024000536C25","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"2024121115361942200_hem2024000536C26","doi-asserted-by":"crossref","first-page":"151216","DOI":"10.1016\/j.soncn.2021.151216","article-title":"The unique symptom burden of patients receiving CAR T-cell therapy","volume":"37","author":"Whisenant","year":"2021","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"2024121115361942200_hem2024000536C27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bjh.18677","article-title":"Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy","volume":"201","author":"Wang","year":"2023","journal-title":"Br J Haematol"},{"key":"2024121115361942200_hem2024000536C28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12955-015-0362-x","article-title":"Equivalence of electronic and paper administration of patient-reported outcome measures: a systematic review and meta-analysis of studies conducted between 2007 and 2013","volume":"13","author":"Muehlhausen","year":"2015","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2024121115361942200_hem2024000536C29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2010.29.8315","article-title":"Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial","volume":"29","author":"Cleeland","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024121115361942200_hem2024000536C30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient- reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115361942200_hem2024000536C31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115361942200_hem2024000536C32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11136-017-1759-2","article-title":"Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma","volume":"27","author":"Shah","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"2024121115361942200_hem2024000536C33","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1038\/s41598-024-62307-5","article-title":"Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma","volume":"14","author":"Cleeland","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"2024121115361942200_hem2024000536C34","first-page":"501","article-title":"Building the foundation for patient-reported outcomes\u2014infrastructure and methodologies","volume":"25","author":"AMCP Partnership","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"2024121115361942200_hem2024000536C35","doi-asserted-by":"crossref","first-page":"100783","DOI":"10.1016\/j.asmr.2023.100783","article-title":"Validated wearable device shows acute postoperative changes in sleep patterns consistent with patient-reported outcomes and progressive decreases in device compliance after shoulder surgery","volume":"5","author":"Gadangi","year":"2023","journal-title":"Arthrosc Sports Med Rehabil"},{"issue":"12","key":"2024121115361942200_hem2024000536C36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","article-title":"Patient-reported outcomes in cancer care\u2014hearing the patient voice at greater volume","volume":"14","author":"LeBlanc","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2024121115361942200_hem2024000536C37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/102\/2346757\/102wang.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/102\/2346757\/102wang.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:51:34Z","timestamp":1733946694000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/102\/526203\/Patient-reported-outcomes-after-CAR-T-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000536","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}